These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32624447)

  • 1. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
    Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
    Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].
    Deng JJ; Jin XY; Zhang ZY; Zhou HX; Yang GZ; Geng CY; Jian Y; Chen WM; Gao W
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):645-650. PubMed ID: 39231768
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
    Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
    Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
    Peña C; Riva E; Schutz N; Ramírez A; Vásquez J; Del Carpio D; Seehaus C; Ochoa P; Vengoa R; Duarte P; Martínez-Cordero H; Figueredo Y; Ríos RO; Ramírez J; Bove V; Roa M; Russo M; Espinoza M; Rodriguez G; Remaggi G; Enciso ME; Chandía M; Fantl D;
    Leuk Lymphoma; 2023 Apr; 64(4):816-821. PubMed ID: 36695519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
    Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
    Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
    Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
    Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M
    Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
    Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
    Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.
    Gonsalves WI; Rajkumar SV; Go RS; Dispenzieri A; Gupta V; Singh PP; Buadi FK; Lacy MQ; Kapoor P; Dingli D; Lust JA; Zeldenrust SR; Hayman SR; Kyle RA; Gertz MA; Kumar SK
    Blood; 2014 Aug; 124(6):907-12. PubMed ID: 24957143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
    Deng J; Qin X; Ma G; Shen X; Sun J; Zhao Y; Zhang Z; Sun Y; Jie G; Su L; Ma J; Tian W; Yang L; Wang Q; Huang H; Shi M; Ma Y; Gao W; Chen W
    Ann Hematol; 2024 Sep; 103(9):3691-3699. PubMed ID: 39073588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.